ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum

A buzzy RNAi startup is going public via an upsized $446.3 million Nasdaq listing, adding to the biopharma industry's high IPO velocity. ADARx Pharmaceuticals, the latest entrant onto the public markets,